GlaxoSmithKline Pharmaceuticals Stock: Price History and Returns
GLAXO.NSGlaxoSmithKline Pharmaceuticals's share price rose by 7.2% a year over the last 10 years, 101.2% in total (in INR). With dividends reinvested the return was +9.5% a year, +147.7% in total. The dividend yield is 2.09% today.
This shows what GlaxoSmithKline Pharmaceuticals Limited has returned on the stock market in the past. Past returns say nothing about the future.
Daily figure as of 22 Nov 2026
Share Price Since 2006
How GlaxoSmithKline Pharmaceuticals Has Performed
5 of 19 full calendar years since 2007 ended with a loss. The stock had recovered its largest drawdown of 45.3% between March 2016 and March 2018 by January 2024, 6 years after the low. Dividends made a big difference: over 10 years they added 2.3 percentage points a year. Since the low in March 2018 the share price has risen more than twofold.
The longest run of gains lasted from 2018 to 2021, four years in a row. The best year was 2010 at +45%, the weakest 2022 at −24.9%. From 2016 to 2017 the stock fell two years in a row. At +9.8%, 2025 was close to the 10-year average of +7.2% a year. Since the start of the year the stock is up 10.3%.
How GlaxoSmithKline Pharmaceuticals Compares
Over 10 years GlaxoSmithKline Pharmaceuticals trailed the MSCI World: with dividends +6.1% a year against +12.1% for the index, in US dollars. Over one year, GlaxoSmithKline Pharmaceuticals trailed 63% of the 27 other stocks in the Drug Manufacturers (General) industry. Over five years, by contrast, GlaxoSmithKline Pharmaceuticals did better than 70% of the industry. The highest share price returns over five years in the Drug Manufacturers (General) industry came from Eli Lilly, Otsuka Holdings and Orion.
| Period | GlaxoSmithKline Pharmaceuticals | MSCI World |
|---|---|---|
| 1 year | +6.1% | +7.3% |
| 5 years | +8.8% | +8.7% |
| 10 years | +6.1% | +12.1% |
Returns of Industry Peers
Among its industry peers, Organon led over one year (+94.8%) and Virbac trailed furthest (−1.4%).
| Stock | 1 year | 5 years |
|---|---|---|
| CSPC Pharmaceutical Group | +2.6% | −4.6% |
| Grifols | +7.5% | −38.1% |
| Ono Pharmaceutical | +19.5% | +0.8% |
| Organon | +94.8% | −55.6% |
| Virbac | −1.4% | −21.5% |
What Became of $1,000
$1,000 invested in GlaxoSmithKline Pharmaceuticals 20 years ago is worth $2,369 today, $3,716 with dividends reinvested.
With dividends means each dividend is reinvested at the closing price on the ex-date, before taxes and costs. The index is represented by an accumulating ETF, dollar amounts at ECB rates. Industry figures are share price returns only, in each exchange's currency, as of 22 Nov 2026.
Returns by Period
| Period | Total | Per year |
|---|---|---|
| 1 year | +8.3% | +8.3% |
| 3 years | +65.5% | +18.3% |
| 5 years | +66.3% | +10.7% |
| 10 years | +101.2% | +7.2% |
| 15 years | +172.9% | +6.9% |
| 20 years | +390.2% | +8.3% |
Returns by Calendar Year
Figures as a table
| Year | Closing price | Return |
|---|---|---|
| 2026 to date | $29.43 | +10.3% |
| 2025 | $26.69 | +9.8% |
| 2024 | $24.30 | +18.6% |
| 2023 | $20.48 | +43.9% |
| 2022 | $14.23 | −24.9% |
| 2021 | $18.95 | +8.2% |
| 2020 | $17.52 | +0.8% |
| 2019 | $17.38 | +6.3% |
| 2018 | $16.35 | +21.7% |
| 2017 | $13.43 | −8.8% |
| 2016 | $14.73 | −17.6% |
| 2015 | $17.88 | +3.6% |
| 2014 | $17.26 | +6.7% |
| 2013 | $16.18 | +38.3% |
| 2012 | $11.70 | +11.5% |
| 2011 | $10.49 | −16.8% |
| 2010 | $12.61 | +45% |
| 2009 | $8.70 | +40.1% |
| 2008 | $6.21 | +12% |
| 2007 | $5.54 | −11.7% |
Peak Price and Largest Drawdown
This is the pure share price return in INR from closing prices, adjusted for stock splits. Dividends come on top and are not included here.
Work out your own amount and period in the What-if calculatorData and Required Disclosures
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026; valuation signal Overvalued since 22 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2026. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
